Drug Companies’ Data Boosts AI Protein Models
For drug discovery, protein-folding models like AlphaFold face a data shortage. To improve these AI tools, pharmaceutical companies are sharing proprietary datasets of proteins interacting with drugs. A consortium trained an open-source model on over 20,000 such structures and found it outperformed public models by significantly improving prediction accuracy. This suggests that making more of…
1 source primary source
Key points
- Pharmaceutical companies share proprietary protein-ligand interaction data
- OpenFold3 model trained on more than 20,000 internal structures outperforms public models
- AISB Network fine-tunes OpenFold3 on company-specific datasets
Read the original at Nature Machine Learning primary sourceOpen source ↗
Topics · follow one to build your own front page
The headline, key points and digest above were generated by Digest AI's editorial model from the linked sources. Automated summaries can contain errors: the sources are the record. Spotted a mistake? Tell us. Published by Martin K., who runs Digest AI and handles corrections.
More in Generative AI & Models
All →- Google launches Gemini 4 Argon model globally for Pro and Ultra subscribers with introductory API pricing · 32 src
- Meta releases Muse Spark Open, an 816B-parameter open-weight multimodal model with 42B active parameters and 1M-token context · 20 src
- Microsoft AI chief says in-house model beats OpenAI's using quarter of compute · 1 src
- NVIDIA releases Nemotron 3.5 Super VL and Bolt edge models for enterprise agents · 8 src
- Black Forest Labs releases FLUX 3 Image Klein, a 5.6B-Parameter Open-Weights model for text-to-image generation · 3 src
Comments
via GitHub Discussions